EcoDrugPlus

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSFCAG00000025234
Gene Symbol: PPARD
5 Cross references
420 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSFCAG00000006231
Gene Symbol: PPARG
5 Cross references
406 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSFCAG00000018737
Gene Symbol: PIK3CA
5 Cross references
274 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSFCAG00000002828
Gene Symbol: PIK3CB
5 Cross references
216 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSFCAG00000026305
Gene Symbol: PIK3CD
5 Cross references
214 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSFCAG00000004554
Gene Symbol: PIK3CG
5 Cross references
215 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSFCAG00000012867
Gene Symbol: PDE10A
5 Cross references
207 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSFCAG00000000972
Gene Symbol: PDE3A
5 Cross references
258 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSFCAG00000022296
Gene Symbol: PDE3B
5 Cross references
204 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSFCAG00000004881
Gene Symbol: PDE4A
5 Cross references
250 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSFCAG00000030002
Gene Symbol: PDE4B
5 Cross references
298 Possible Orthologues:

Phosphodiesterase 4c

Ensembl ID : ENSFCAG00000007525
Gene Symbol: PDE4C
5 Cross references
88 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).